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Purpose
The Ayurvedic nerve tonic herb Centella asiatica demon-
strates potential neuro-regenerative properties in in vitro
and in vivo models. The aims of the present study were to
evaluate the safety and therapeutic effects of CAST
(Indena
®, Milan, Italy) in humans with DN, while moni-
toring the stability of CAST during the trial period.
Methods
The stability of CAST was monitored throughout the
study using reversed phase high performance liquid chro-
matography. CAST or placebo capsules were administered
to 33 DN subjects, in a randomized double-blind, placebo-
controlled study. The dose of CAST was escalated from
60 mg to 240 mg/day over the first 12 weeks, followed by
a stable dose of 240 mg/day for the remaining 40 weeks.
The primary outcome was total symptom score (TSS),
while secondary outcomes were nerve conduction studies,
neurological disability score (NDS) and qualitative sensory
testing (QST).
Results
CAST was stable (<10% change from starting values) at
room temperature for the duration of the study. At base-
line, there was no difference in outcome measures
between treatment (n=15, 3F/12M) and placebo (n=18,
6F/12M) groups (TSS: 8.4±2.9 vs 8.3±2.5; combined sen-
sory nerve action potential amplitude of sural and radial
(SNAP): 18.8±8.9 vs 17.7±15.4 μV). At week 52, subjects
in the treatment group had significantly lower TSS scores
(6.4±0.4 vs 7.5±0.4, p<0.05) and higher SNAP (20.3±2.4 vs
14.8±2.2 μV, p<0.05) than the placebo group. Other
outcome measures did not differ significantly between the
two groups.
Conclusion
CAST was stable and well tolerated by subjects at up to
240 mg per day. Compared to placebo, CAST significantly
improved subjective DN symptoms (TSS score) and pre-
vented deterioration in an objective measure of nerve con-
duction (SNAP). Current treatments for DN provide
symptomatic relief rather than ameliorating disease pro-
gression. Multicenter trials are clearly warranted to further
evaluate the role of CAST as a novel disease-modifying
agent for DN.
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